LAG-3 Antagonist - Pipeline Insight, 2025
A new report, "LAG-3 Antagonist - Pipeline Insight, 2025," offers a comprehensive overview of over 20 companies and 20 drug development projects in the LAG-3 antagonist landscape.
ResearchAndMarkets.com released its report, "LAG-3 Antagonist - Pipeline Insight, 2025," in May 2024. The publication provides an in-depth analysis of the development landscape for LAG-3 antagonists, featuring over 20 companies and 20 drug development projects.
LAG-3, or Lymphocyte Activation Gene-3, is a molecule involved in immune system regulation. Its blockade with monoclonal antibodies can augment T-cell function, making it a target for cancer immunotherapies, often in combination with PD-1 inhibitors.
The report details drugs in various stages of clinical and preclinical development, assessing therapies by product type, stage, route of administration, and molecule type. It also identifies inactive pipeline products.
Notable drug candidates highlighted include MacroGenics' Tebotelimab, a bispecific antibody targeting both PD-1 and LAG-3. Novartis is also developing LAG525, a humanized antibody-based LAG-3 inhibitor for solid tumors.
Companies like Bristol-Myers Squibb and Ono Pharmaceuticals are noted as being in the most advanced stages of LAG-3 antagonist development, with products in Phase II/III. The report compiles information on development efforts from over 20 key players in the field.